Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
U.S. Army Medical Research and Materiel Command
ClinicalTrials.gov Identifier:
NCT00606580
First received: January 21, 2008
Last updated: June 11, 2014
Last verified: June 2014

January 21, 2008
June 11, 2014
January 2008
July 2011   (final data collection date for primary outcome measure)
Final Clinical Cure Rate [ Time Frame: Day 42, 98, and 168 ] [ Designated as safety issue: No ]

Final clinical cure was defined as an index lesion that met the criteria for initial clinical cure without relapse. Definitions for index lesion outcomes were as follows:

  • Initial Clinical Improvement: At least 50% to 99% reduction in the size of the measured lesion from the baseline measurement by the Day 42 evaluation.
  • Initial Clinical Cure: 100% re-epithelialization (ie, a 0 x 0 length x width measurement) of the lesion at the nominal Day 42 evaluation, or initial clinical improvement followed by 100% re-epithelialization by Day 98.
  • Relapse: Initial clinical cure followed by re-ulceration by Day 168, or initial clinical improvement followed by lesion enlargement by Day 168.
  • Final Clinical Cure: Initial clinical cure without relapse through study Day 168.Clinical Failure: Lack of at least initial clinical improvement by Day 42, or relapse.
WR 279,396 is superior to placebo in lesion healing [ Time Frame: 48 days ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00606580 on ClinicalTrials.gov Archive Site
  • Final Clinical Cure Rate (Per Protocol Dataset) [ Time Frame: Day 42, 98, and 168 ] [ Designated as safety issue: No ]
    Final clinical cure was defined as an index lesion that met the criteria for initial clinical cure without relapse. Definitions for index lesion outcomes as described in the primary outcome measure.
  • Estimated Percentage Subjects With Re-epithelialization of the Index Lesion Without Relapse [ Time Frame: Day 42 ] [ Designated as safety issue: No ]
    For the first of the above analyses, subjects were considered to have endpoint events at the first assessment on or before Day 42 where complete re-epithelialization occurred at the index lesion that was not followed by a later assessment where ulceration was present. Subjects who did not have complete re-epithelialization by Day 42 or who relapsed after Day 42 were censored in the analysis at the Day 42 assessment. This analysis was only to be conducted through Day 42.
  • Estimated Percentage of Subjects With Re-epithelialization of the Index Lesion Without Relapse at Various Times of Follow-up [ Time Frame: Days 42, 49, and 98 ] [ Designated as safety issue: No ]
  • Estimated Percentage of All Treated Ulcerated Lesions Without Relapse at Day 42 [ Time Frame: Days 42 ] [ Designated as safety issue: No ]
  • Estimated Percentage of All Treated Ulcerated Lesions Without Relapse at Day 49 [ Time Frame: Days 49 ] [ Designated as safety issue: No ]
  • Estimated Percentage of All Treated Ulcerated Lesions Without Relapse at Day 98 [ Time Frame: Days 98 ] [ Designated as safety issue: No ]
  • Number of Subjects Achieving Initial Clinical Improvement of the Index Lesion [ Time Frame: Day 42 ] [ Designated as safety issue: No ]
  • Number of Subjects Achieving Re-epithelialization of the Index Lesion Without Relapse [ Time Frame: Day 168 ] [ Designated as safety issue: No ]
    Number of Subjects Achieving Re-epithelialization of the Index Lesion by Day 42 without Relapse from Day 42 Onward, Imputing Relapse for any Subject with a Missing Visit after Day 42
  • Number of Subjects Achieving Re-epithelialization of All Treated Ulcerated Lesions Without Subsequent Relapse [ Time Frame: Day 168 ] [ Designated as safety issue: No ]
    Number of Subjects Achieving Re-epithelialization of All Treated Ulcerated Lesions at Day 42 without Subsequent Relapse from Day 42 Onward,
  • Number of All Ulcerated Lesions Achieving 100% Re-epithelialization by Day 42 [ Time Frame: Day 42 ] [ Designated as safety issue: No ]
  • Number of Subjects With a Relapse on or After Day 42 [ Time Frame: Day 168 ] [ Designated as safety issue: No ]
Paromomycin topical cream is superior to placebo in lesion healing [ Time Frame: 48 days ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)
A Pivotal, Randomized, Double-blind, Vehicle-controlled Study to Evaluate WR 279,396 and Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)

This study will test the ability of the topical cream WR 279,396 to treat the skin lesions caused by the parasite called leishmania. WR 279,396 is an antibiotic preparation that contains paromomycin + gentamicin. This cream will be compared to the effect of a topical cream containing paromomycin alone and to a placebo cream that contains no antibiotics. Therefore, this study will have three groups of patients, and they will be assigned to one of these treatments randomly. The study will be carried out without the patient or the physician knowing which cream is being used for which patient. The goal is to determine if WR 279,396 cream or the paromomycin cream is better than placebo, and if WR 279,396 is better than paromomycin alone.

This is an efficacy study to test the ability of WR 279,396 topical cream to treat uncomplicated cutaneous leishmaniasis caused primarily by Leishmania major in adults and children in Tunisia where the disease in endemic. A total of 375 volunteers will be randomized to the three arms described above to determine product efficacy. Safety data in all three arms will also be collected.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Cutaneous Leishmaniasis
  • Drug: WR 279,396 topical cream
    WR 279,396 is a topical antibiotic cream containing 15% paromomycin and 0.5% gentamicin that will be applied to each lesion once a day and covered with a sterile gauze and tape dressing.
  • Drug: Paromomycin Alone topical cream
    The antibiotic paromomycin 15% in the same topical cream used in arm 1 will be applied to lesions daily and covered with a protective sterile gauze and tape dressing.
  • Drug: Vehicle placebo cream
    Applied daily to cutaneous leishmaniasis lesions, primarily ulcerative, and covered with a protective, sterile gauze and tape dressing.
  • Experimental: WR 279,396 Topical Treament
    WR 279,396 topical cream (15% paromomycin + 0.5% gentamicin topical cream)
    Intervention: Drug: WR 279,396 topical cream
  • Experimental: Paromomycin Alone Topical treatment
    Paromomycin Alone topical cream (15% paromomycin topical cream)
    Intervention: Drug: Paromomycin Alone topical cream
  • Placebo Comparator: Vehicle Placebo Cream
    The cream base without the addition of paromomycin or gentamicin
    Intervention: Drug: Vehicle placebo cream
Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J, Gharbi A, Belhadj Hamida N, Boukthir A, Chlif S, Abdelhamid K, El Ahmadi Z, Louzir H, Mokni M, Morizot G, Buffet P, Smith PL, Kopydlowski KM, Kreishman-Deitrick M, Smith KS, Nielsen CJ, Ullman DR, Norwood JA, Thorne GD, McCarthy WF, Adams RC, Rice RM, Tang D, Berman J, Ransom J, Magill AJ, Grogl M. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med. 2013 Feb 7;368(6):524-32. doi: 10.1056/NEJMoa1202657.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
375
July 2011
July 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • The subject was age 5 years or older, but less than 65 years.
  • The subject was able to understand the information provided to him/her and give written informed consent. Consent was obtained from the parent/guardian of subjects who were < 18 years old. Children 12 to < 18 years old were asked to sign the written assent form. Witnessed verbal assent was obtained from subjects 5 to 11 years old.
  • The subject was a male or female who was generally healthy.
  • The subject had cutaneous lesions diagnosed as leishmaniasis in the index lesion by: (1) the identification of promastigotes in a culture of an aspirated lesion, or (2) the microscopic identification of Leishmania amastigotes on a DifQuik or Giemsa stained smear obtained from a lesion scraping.
  • The subject had five or fewer cutaneous lesions.
  • The subject had one lesion, which would be designated as the index lesion, that was ≥ 1 and < 5 cm in its greatest diameter and primarily ulcerative, ie, not purely verrucous or nodular.
  • The subject was willing to forego other forms of treatment for CL, including other investigational treatment during the study.
  • In the opinion of the principal investigator, the subject or subject's parent/guardian was capable of understanding and complying with the protocol

Exclusion Criteria

  • The subject received previous treatment for leishmaniasis (including WR 279,396) within the last 6-months, with the exception of mercurochrome.
  • The subject had difficulty complying with instructions on maintaining the dressing, eg, due to life style activities or age.
  • The subject had only a single lesion whose characteristics included any of the following: verrucous or nodular lesion, ≥ 5 cm in its greatest diameter, < 1 cm or located on the ear, or other location that in the opinion of the principal investigator would be difficult to maintain application of study drug topically.
  • The subject had a lesion due to Leishmania that involved the mucosa.
  • The subject had signs or symptoms of disseminated disease, ie, clinically significant lymphadenitis with nodules that were painful and > 1 cm in the lymphatic drainage of the ulcer.
  • The subject was a female with a positive urine pregnancy test, or who was breast feeding or lactating.
  • The subject had an active malignancy or had a history of a solid, metastatic or hematologic malignancy, with the exception of a basal or squamous cell carcinoma of the skin that had been removed.
  • The subject had a significant organ abnormality or chronic disease that, in the opinion of the investigator, would warrant exclusion of the subject from the study or would prevent the subject from completing the study.
  • The subject was receiving any of the following medications: any medication containing pentavalent antimony, including stibogluconate sodium (Pentostam®) and meglumine antimoniate (Glucantime®); amphotericin B, including liposomal amphotericin B and amphotericin B deoxycholate; other medications containing paromomycin (administered IV or topically); methylbenzethonium chloride, fluconazole, ketoconazole, itraconazole; pentamidine; or allopurinol.
  • The subject or the subject's parent/guardian was unable to understand verbal and/or written Arabic, English, or French (languages in which certified translations of the informed consent were available).
  • The subject presented with an immuno-compromising condition, including recidivant leishmaniasis (during the past 2 years), or diabetes.
  • The subject had a history of known or suspected idiosyncratic reactions or hypersensitivity to aminoglycosides.
Both
5 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Tunisia
 
NCT00606580
A-14134
No
U.S. Army Medical Research and Materiel Command
U.S. Army Medical Research and Materiel Command
Not Provided
Principal Investigator: Afif Ben Salah, M.D., Ph.D. Institute Pasteur Tunisia
U.S. Army Medical Research and Materiel Command
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP